NEW YORK (GenomeWeb News) – Trovagene said after the close of the market Tuesday that it has raised gross proceeds of $3.8 million from a private placement of stock and warrants.

The San Diego-based molecular diagnostics developer placed 940,000 units at a purchase price of $4 per unit. Each consists of one share of unregistered common stock and one warrant to purchase one share of common stock. The warrants are exercisable for five years from the date of closing at an exercise price of $5.32 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.